By expenditures
| Name | Title | Type |
|---|---|---|
| Bryce Radke | Financial Reporting Manager | Auditee |
| Aycha Sawa | Chief Financial Officer | Auditee |
| Martha Kreitzman | INTERIM CHIEF FINANCIAL OFFICER | Auditee |
| Wendi Unger | Principal | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 399474 | 2025 | 2026-04-22 | CLIFTONLARSONALLEN LLP | $318.84M |
| 366326 | 2024 | 2025-09-15 | Baker Tilly US LLP | $534.34M |
| 339133 | 2023 | 2025-01-21 | Baker Tilly US LLP | $435.65M |
| 28121 | 2022 | 2023-03-29 | Baker Tilly US LLP | $315.63M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 399474 | 2025 | 2026-04-22 | 1208490 | 2025-009 | Material Weakness | Yes | ABL |
| 399474 | 2025 | 2026-04-22 | 1208489 | 2025-007 | Material Weakness | Yes | N |
| 399474 | 2025 | 2026-04-22 | 1208488 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208487 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208486 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208485 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208484 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208483 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208482 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208481 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208480 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208479 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208478 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208477 | 2025-006 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208476 | 2025-005 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208475 | 2025-005 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208474 | 2025-005 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208473 | 2025-005 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208472 | 2025-005 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208471 | 2025-005 | Material Weakness | Yes | AB |
| 399474 | 2025 | 2026-04-22 | 1208470 | 2025-005 | Material Weakness | Yes | AB |
| 366326 | 2024 | 2025-09-15 | 1153083 | 2024-012 | Material Weakness | Yes | G |
| 366326 | 2024 | 2025-09-15 | 1153082 | 2024-012 | Material Weakness | Yes | G |
| 366326 | 2024 | 2025-09-15 | 1153081 | 2024-012 | Material Weakness | Yes | G |
| 366326 | 2024 | 2025-09-15 | 1153080 | 2024-011 | Material Weakness | Yes | L |
| 366326 | 2024 | 2025-09-15 | 1153079 | 2024-010 | Material Weakness | Yes | B |
| 366326 | 2024 | 2025-09-15 | 1153078 | 2024-010 | Material Weakness | Yes | B |
| 366326 | 2024 | 2025-09-15 | 1153077 | 2024-009 | Material Weakness | Yes | B |
| 366326 | 2024 | 2025-09-15 | 1153076 | 2024-009 | Material Weakness | Yes | B |
| 366326 | 2024 | 2025-09-15 | 1153075 | 2024-009 | Material Weakness | Yes | B |
| 366326 | 2024 | 2025-09-15 | 1153074 | 2024-009 | Material Weakness | Yes | B |
| 366326 | 2024 | 2025-09-15 | 1153073 | 2024-010 | Material Weakness | Yes | B |
| 366326 | 2024 | 2025-09-15 | 1153072 | 2024-010 | Material Weakness | Yes | B |
| 339133 | 2023 | 2025-01-21 | 1096300 | 2023-010 | Significant Deficiency | Yes | N |
| 339133 | 2023 | 2025-01-21 | 1096299 | 2023-009 | Significant Deficiency | - | F |
| 339133 | 2023 | 2025-01-21 | 1096298 | 2023-009 | Significant Deficiency | - | F |
| 339133 | 2023 | 2025-01-21 | 519858 | 2023-010 | Significant Deficiency | Yes | N |
| 339133 | 2023 | 2025-01-21 | 519857 | 2023-009 | Significant Deficiency | - | F |
| 339133 | 2023 | 2025-01-21 | 519856 | 2023-009 | Significant Deficiency | - | F |
| 28121 | 2022 | 2023-03-29 | 613336 | 2022-004 | Significant Deficiency | - | N |
| 28121 | 2022 | 2023-03-29 | 36894 | 2022-004 | Significant Deficiency | - | N |